An Open-label 8-week Adjunctive-to-insulin and Renal Mechanistic Pilot Trial of BI 10773 in Type 1 Diabetes Mellitus (the ATIRMA Trial)

Trial Profile

An Open-label 8-week Adjunctive-to-insulin and Renal Mechanistic Pilot Trial of BI 10773 in Type 1 Diabetes Mellitus (the ATIRMA Trial)

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2014

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics; Proof of concept
  • Acronyms ATIRMA
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 17 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
    • 27 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
    • 17 Sep 2013 Data will be presented at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD), according to a Boehringer Ingelheim and Eli Lilly media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top